<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Evidence-based guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-Intensive Care and Emergency Medicine.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Torbey MT, BÃ¶sel J, Rhoney DH, Rincon F, Staykov D, Amar AP, Varelas PN, JÃ¼ttler E, Olson D, Huttner HB, Zweckberger K, Sheth KN, Dohmen C, Brambrink AM, Mayer SA, Zaidat OO, Hacke W, Schwab S. Evidence-based guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine. Neurocrit Care. 2015 Feb;22(1):146-64. [172 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25605626&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions of the strength of recommendations (&lt;em&gt;strong&lt;/em&gt;, &lt;em&gt;weak&lt;/em&gt;) and quality of the evidence (&lt;em&gt;high&lt;/em&gt;, &lt;em&gt;moderate&lt;/em&gt;, &lt;em&gt;low&lt;/em&gt;, &lt;em&gt;very low&lt;/em&gt;) are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Airway Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What are the indications for intubation and extubation in large hemispheric infarction (LHI)? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What is the best timing for tracheostomy in LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;LHI patients with signs of respiratory insufficiency or neurological deterioration should be intubated immediately (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Extubation should be attempted in LHI patients who meet the following criteria, even if communication and cooperation cannot be established (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Successful spontaneous breathing trials &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Absence of oropharyngeal saliva collections &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Absence of demand for frequent suctioning &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Presence of cough reflex and tube intolerance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Free of analgesia and sedation &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tracheostomy should be considered in LHI patients failing extubation or in whom extubation is not feasible by 7 to 14 days from intubation (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hyperventilation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Does hyperventilation effectively treat increased intracranial pressure (ICP) in LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend against prophylactic hyperventilation in LHI patients (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest using hyperventilation for short period of time as a rescue maneuver in LHI patients showing clinical signs of brain herniation (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Analgesia and Sedation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Should analgesia and/or sedation be administered in LHI patients? If so, which pharmacologic agents should be used? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Are daily wake-up trials recommended? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend analgesia and sedation if signs of pain, anxiety, or agitation arise in LHI patients (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend the lowest possible sedation intensity and earliest possible sedation cessation, while avoiding physiologic instability and discomfort in LHI patients (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend against the routine use of daily wake-up trials in LHI patients. Caution is particularly warranted in patients prone to ICP crises. Neuromonitoring of at least ICP and cerebral perfusion pressure (CPP) is recommended to guide sedation, and daily wake-up trials should be abandoned or postponed at signs of physiological compromise or discomfort (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Gastrointestinal Tract&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;How should dysphagia be assessed in LHI patients? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When should LHI patients receive a nasogastric tube? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When should LHI patients receive a percutaneous enterogastric tube? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest dysphagia screening in the early phase of LHI. Dysphagia can be assessed once the patient is weaned from sedation and ventilation (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;LHI patients with dysphagia should receive a nasogastric tube as soon as possible (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that high National Institute of Health Stroke Scale (NIHSS) scores and persisting dysphagia on endoscopic swallowing should prompt discussion with the family on placement of a percutaneous endoscopic gastrostomy (PEG) tube between weeks 1 and 3 of the intensive care unit (ICU) stay (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Glucose Control&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;How should glucose be controlled in LHI patients?&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend that hypoglycemia and hyperglycemia should be avoided in LHI. Intermediate glycemic control (serum glucose level 140&amp;ndash;180 mg/dL) should be the target of insulin therapy in LHI patients (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend that intravenous sugar solutions should be avoided in LHI (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hemoglobin Control&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What is the optimal hemoglobin level in LHI patients? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend maintaining a hemoglobin of 7 g/dL or higher in LHI patients (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should also consider specific situations such as planned surgery, hemodynamic status, cardiac ischemia, active significant bleeding, and arteriovenous oxygen extraction compromise when determining the ideal hemoglobin for a patient (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider reducing blood sampling wherever possible in order to decrease the risk of anemia in LHI (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Deep Venous Thrombosis Prophylaxis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;How should deep venous thrombosis (DVT) prophylaxis be administered to LHI patients? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend early mobilization to prevent DVT in hemodynamically stable LHI patients with no evidence of increased ICP (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend DVT prophylaxis for all LHI patients upon admission to the ICU and for the duration of immobilization (&lt;em&gt;strong recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using intermittent pneumatic compression (IPC) for DVT prophylaxis (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using low molecular weight heparin (LMWH) for DVT prophylaxis (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend against the use of compression stockings for DVT prophylaxis (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anticoagulation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If LHI is due to a cardioembolic mechanism or if the patient has high thromboembolic risk, when should anticoagulation be initiated after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that oral anticoagulation be reinitiated 2 to 4 weeks after LHI in patients at high thromboembolic risk (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that earlier re-initiation of oral anticoagulation should be based on clinical risk assessment and additional diagnostic tests (e.g., prosthetic valve, acute DVT, acute pulmonary embolism (PE), or transesophageal echocardiography (TEE) showing intracardiac thrombus) (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest using aspirin during the period of no anticoagulation in LHI with atrial fibrillation (AF) or increased thromboembolic risk, provided surgery is not imminent (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Blood Pressure Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What is the optimal blood pressure in LHI patients? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend that clinicians follow current blood pressure management guidelines for ischemic stroke in general when caring for LHI patients. Maintain a mean arterial pressure (MAP) &amp;gt;85 mm Hg in ischemic stroke without hemorrhagic transformation. Lower systolic blood pressure (SBP) to &amp;lt;220 mm Hg (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest avoiding blood pressure variability, especially in the early phase of LHI treatment (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Steroid Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Do steroids effectively reduce brain edema in LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend against using steroids for brain edema in patients with LHI (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Barbiturate Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Do barbiturates effectively treat brain edema in LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Barbiturate therapy is not recommended in patients with LHI because the risks outweigh the benefits (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Temperature Control&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Does hypothermia or normothermia have any role in the management of brain edema after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest considering hypothermia as a treatment option in patients who are not eligible for surgical intervention (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If hypothermia is considered, the authors suggest a target temperature of 33&amp;deg; to 36&amp;deg; Celsius for duration of 24 to 72 hours (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest maintaining normal core body temperature (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Head Position&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What is the optimal head position in patients with LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest a horizontal body position in most patients with LHI. However in patients with increased ICP, they suggest a 30&amp;ordm; backrest elevation (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Osmotic Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Does osmotic therapy effectively treat brain edema and improve outcome in LHI? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What are the potential complications associated with the use of these agents? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using mannitol and hypertonic saline for reducing brain edema and tissue shifts in LHI only when there is clinical evidence of cerebral edema (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest using osmolar gap instead of serum osmolality to guide mannitol dosing and treatment duration &lt;em&gt;(weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertonic saline dosing should be guided by serum osmolality and serum sodium (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using mannitol cautiously in patients with acute renal impairment (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using hypertonic saline cautiously in patients with volume overload states (i.e., heart failure, cirrhosis, etc.) since this agent will expand intravascular volume (&lt;em&gt;strong recommendation, high quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Neuroimaging by Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Can neuroimaging by CT or MRI predict neurological deterioration and &quot;malignant&quot; course after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend using early changes on CT and MRI to predict malignant edema after LHI (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ultrasound&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What is the value of transcranial Doppler (TCD) and transcranial color-coded duplex (TCCS) sonography for the prediction of malignant course after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest using TCCS as a complementary test to predict malignant course and possibly as a primary test if the patient is too unstable to be transferred outside the ICU for neuroimaging (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evoked Potentials&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Can evoked potentials be used to predict malignant course after large hemispheric stroke? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest considering brainstem auditory evoked potentials (BAEPs) as a complementary method to predict malignant course within the first 24 h after middle cerebral artery (MCA) infarction, particularly in patients too unstable to be transported to neuroimaging (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Electroencephalography (EEG)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Can EEG predict a malignant course after LHI? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is there a utility for continuous EEG monitoring in patients with LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest considering EEG in the first 24 h after stroke to assist with predicting clinical course in LHI (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that continuous and quantitative EEG represent a promising non-invasive monitoring technique and a tool for estimation of prognosis after LHI that might be useful in the future pending further study (&lt;em&gt;weak recommendation, very low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Invasive Multimodal Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Can invasive multimodal monitoring (ICP, microdialysis, brain tissue oxygen [ptiO&lt;sub&gt;2&lt;/sub&gt;]) predict malignant course after LHI? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What is the value of invasive multimodal monitoring in preventing secondary complications after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Invasive multimodal monitoring has not been sufficiently studied, and therefore cannot be recommended in the routine management of LHI (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Surgical Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Should decompressive hemicraniectomy (DHC) be offered to patients with LHI? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What are the selection criteria for DHC in LHI? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What is the optimal timing and size for DHC? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Should age and hemispheric dominance play a role in the decision to offer DHC to LHI patients? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Should temporal lobectomy or duraplasty be offered as an adjunct therapy to DHC? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend DHC as a potential therapy to improve survival after LHI regardless of patient age (&lt;em&gt;strong recommendation, high quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients older than 60 years, the authors recommend taking in consideration patients and family wishes, since in this age group, DHC can reduce mortality rate but with a higher likelihood of being severely disabled (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is currently insufficient data to recommend against DHC in LHI patients based on hemispheric dominance (&lt;em&gt;strong recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To achieve the best neurological outcome, the authors recommend performing DHC within 24 to 48 h hours of symptom onset and prior to any herniation symptoms (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend a size of 12 cm as an absolute minimum for DHC. Larger sizes of 14 to 16 cm seem to be associated with better outcomes (&lt;em&gt;strong recommendation, moderate quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that lobectomy or duraplasty should only be considered as an individualized treatment option (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that the resection of the temporal muscle should only be considered as an individualized treatment option (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ethical Considerations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Is the reduction of mortality after DHC achieved at the expense of functional dependency? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is modified Rankin scale (mRS) score of 4 considered a desirable outcome after LHI? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that the decision to perform DHC should depend on values and preferences of patients and relatives regarding survival and dependency (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Quality of Life (QoL)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Is survival after LHI associated with good QoL? &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors suggest that future research use QoL as an outcome measure in LHI patients (&lt;em&gt;weak recommendation, low quality of evidence&lt;/em&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria for Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria for Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors are very confident that the true effect lies close to that of the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors' confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Strength of Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The desirable effects of an intervention clearly outweigh the undesirable effects, or clearly do not.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The risks and benefits of an intervention are less certain&amp;mdash;either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Large hemispheric infarction (LHI), also known as malignant middle cerebral infarction&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Evaluation" />
      <FieldValue Value="Management" />
      <FieldValue Value="Prevention" />
      <FieldValue Value="Risk Assessment" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Critical Care" />
      <FieldValue Value="Emergency Medicine" />
      <FieldValue Value="Neurological Surgery" />
      <FieldValue Value="Neurology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Allied Health Personnel" />
      <FieldValue Value="Emergency Medical Technicians/Paramedics" />
      <FieldValue Value="Hospitals" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide evidence-based recommendations for the critical care management of patients following large hemispheric infarction (LHI)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients with large hemispheric infarction (LHI)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Airway management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Intubation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Extubation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Tracheostomy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rescue hyperventilation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Analgesia and sedation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dysphagia screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nasogastric tube placement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Placement of a percutaneous endoscopic gastrostomy (PEG) tube &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glucose control: avoidance of hypoglycemia and hyperglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemoglobin control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Deep venous thrombosis prophylaxis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Early mobilization &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intermittent pneumatic compression (IPC) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Low-molecular-weight heparin &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Temperature control (hypothermia, normothermia) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Head positioning &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Osmotic therapy (mannitol and hypertonic saline) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neuroimaging by computed tomography (CT) and magnetic resonance imaging (MRI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prediction of malignant course&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Transcranial Doppler (TCD) and transcranial color-coded duplex (TCCS) sonography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Brainstem auditory evoked potentials (BAEPs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Electroencephalography (EEG) (continuous and quantitative) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Decompressive hemicraniectomy (DHC) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Lobectomy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Duraplasty &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Resection of the temporal muscle &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ethical considerations &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note:&lt;/strong&gt; The following were considered but not recommended: prophylactic hyperventilation, routine use of daily wake-up trials, intravenous sugar solutions, compression stockings, steroids, barbiturates, invasive multimodal monitoring (intracranial pressure [ICP], microdialysis, brain tissue oxygen [ptiO2]) (not recommended).&lt;/p&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life/neurological outcomes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institute of Health Stroke Scale (NIHSS) scores &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Feasibility and safety of endovascular cooling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency of intracranial pressure (ICP) crises &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rate of deep vein thrombosis (DVT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Utility of diagnostic tests &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Brain Edema Therapy of Large Hemispheric Infarction (LHI)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline authors performed a search of Medline/PUBMED, EMBASE, Cochrane, CINAHL and found 4,695 articles.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Inclusion Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Publication date from 1990/01/01 to 2012/12/31 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type of studies: Humans; Clinical Trials (phase I, phase II, phase III, and phase IV); Classical Articles; Comparative Studies; Controlled Clinical Trials; Evaluation Studies; Meta-Analysis; Multicenter Studies; Randomized Controlled Trials; Systematic Reviews, Validation Studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Language: English &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusion Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Case reports (less than 5 patients) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reviews &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke size unclear &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-large hemispheric infarction (LHI) populations or mixed stroke size population &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;After applying the inclusion and exclusion criteria and eliminating duplicates and non-English articles, the authors hand searched the titles and abstracts and retained 185 studies, which underwent full inspection. After the studies were fully inspected, methods ascertained, and results evaluated, 156 studies were eliminated using the criteria established above, retaining only 30 manuscripts.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Monitoring (Intracranial Pressure [ICP], Microdialysis, Cerebral Blood Flow [CBF], Brain Tissue Oxygen [ptiO2]) in Large Middle Cerebral Artery (MCA) Infarction&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Literature searches were performed in PubMed. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Inclusion Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Studies on monitoring modalities in patients with large hemispheric infarction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Different techniques and approaches to assess ICP, CBF, brain tissue oxygenation, metabolic parameters (e.g., ultrasonography, imaging, positron emission tomography [PET], single-photon emission computed tomography [SPECT], invasive techniques, near-infrared spectroscopy [NIRS], etc.), or pathological changes in electroencephalography (EEG), somatosensory evoked potentials (SSEP), auditory evoked potentials (AEP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sample size minimum (4-5) patients &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusion Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Other diagnostic categories (transient brain injury [TBI], intracerebral hemorrhage [ICH]), or &amp;lt;50% MCA territory affected &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Case reports, too small patient number &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies not focusing on monitoring, or monitoring not playing substantial role in the study design &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Published before 01 Jan 1990 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Language other than English, German, French or Spanish &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The initial search yielded 1367 articles. After review of the titles 227 articles were selected for further evaluation. After reading the abstracts, 73 articles remained for full review. After reading those articles in full text, 46 papers remained. The reference lists of the articles and the publications lists (as accessible on PubMed) of the authors of those papers were additionally screened for missing articles.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Predictors of Poor Outcome after Malignant MCA Stroke&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;PubMed was searched from 8/9/12 to 8/15/12 and covered publication dates from 1990/01/01 to 2012/12/31. Hand searches were carried out from 8/25/12 to 9/25/12.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 41 articles were identified for further review.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Brain Edema Therapy of Large Hemispheric Infarction (LHI)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 30 manuscripts were retained.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Monitoring (Intracranial Pressure [ICP], Microdialysis, Cerebral Blood Flow [CBF], Brain Tissue Oxygen [ptiO2]) in Large Middle Cerebral Artery (MCA) Infarction&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 46 papers remained after full-text review.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Subgroup: Predictors of Poor Outcome after Malignant MCA Stroke&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 41 articles were identified for further review.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria for Quality of Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria for Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The author are very confident that the true effect lies close to that of the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors' confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The authors have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Each subtopic-related expert panel performed a critical literature review and summarized the findings in tables.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For each clinical question, the panel assessed the quality of the data and developed recommendations using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) system. The panel graded the quality of the evidence as very low, low, moderate, or high. The panel considered quality of evidence in terms of the likelihood that the further research would change their level of confidence in the estimate of effect for an intervention (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Consensus Development Conference)" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A committee identified topics of interest based on clinical decision points in the critical care management of large hemispheric infarction (LHI) patients. The committee recruited European and North American experts from the fields of neurosurgery, neurocritical care, neurology, interventional neuroradiology, and neuroanesthesiology, and divided them into different subtopic-related panels based on expertise. Each panel performed a critical literature review and summarized the findings in tables; draft recommendations were prepared based on this data. Before the conference, this draft information was distributed to the larger group of conference participants.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For each clinical question, the panel assessed the quality of the data and developed recommendations using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) system. The panel graded the quality of the evidence as very low, low, moderate, or high (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). The panel considered quality of evidence in terms of the likelihood that the further research would change their level of confidence in the estimate of effect for an intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The GRADE system classifies recommendations as strong or weak, according to the quality of evidence, the balance between risks and benefits, patient preferences, and cost considerations (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field). Evaluating each of these components individually and explicitly is a defining feature of this guideline system. One advantage of GRADE is that it allows for strong recommendations in the setting of lower quality evidence, as long as there are other mitigating factors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At the Neurocritical Care Society (NCS) annual meeting in October 2012, each panel member presented a summary of the data and recommendations to the group. The committee met again in Mannheim, Germany on January 23&amp;ndash;26, 2013 during the German Society for Neuro-Intensive Care and Emergency Medicine annual meeting. The committee reviewed key studies and the recommendations made by individual panel members. The final questions were reviewed at the conference and feedback was obtained from a larger auditorium of interdisciplinary neurocritical care practitioners.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Strength of Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Strength of Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The desirable effects of an intervention clearly outweigh the undesirable effects, or clearly do not.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The risks and benefits of an intervention are less certain&amp;mdash;either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Not stated" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate critical care management of large hemispheric infarction that addresses specific questions that intensivists deal with on a day-to-day basis on rounds&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;There is a risk of bleeding from heparin and warfarin. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although some studies found hypothermia to be generally safe, hypotension, hematologic effects, and infections were common side effects. It is also important to keep in mind the potential side effects of hypothermia such as pneumonia and coagulopathy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mannitol should be used cautiously in patients with acute renal impairment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertonic saline should be used cautiously in patients with volume overload states (i.e., heart failure, cirrhosis, etc.) since this agent will expand intravascular volume. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Computed tomography (CT) scans require patient transportation and expose the patient to radiation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insufficient bone window may represent a limitation of ultrasound-based monitoring in some patients. Another difficulty of sonography is that a reliable ultrasound examination usually requires a skilled and experienced examiner. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The decision about whether or not to perform depressive hemicraniectomy (DHC) must also address its known complications, such as anesthetic risks, surgical risks (pain, infection, bleeding, and extra-axial fluid collections), the &quot;syndrome of the trephined&quot; (headache, seizures, and worsening of neurological deficit), higher rates of hydrocephalus, and the risks of cranioplasty (bleeding, infection). Since large hemispheric infarction (LHI) patients often have many medical co-morbidities, these risks can be substantial. Furthermore, the costs of DHC must be acknowledged, including the direct costs of the procedures and the prolonged hospitalization, as well as the costs of chronic care associated with functional dependency in a patient who might have otherwise died soon after their infarction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The concern of many clinicians has been that a reduction in mortality might be outweighed by a major disability in most survivors, leaving them severely disabled and facing a life of dependency, pain, and hopelessness. Therefore, the choice of performing DHC should hinge on the patient's willingness to accept survival with some degree of disability. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should avoid unnecessary or excessive analgesia and sedation, as this might lead to hypotension, immunosuppression, thromboembolic events, prolonged coma and ventilation, and other agent-specific side effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The International Consensus Conference on Critical Care Management of Patients Following Large Hemispheric Infarct (LHI) was designed to help develop recommendations for treating LHI patients. One significant challenge the reviewers faced was the paucity of large clinical trials addressing important clinical management questions. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) system allowed the panels to make recommendations not based only on the quality of the evidence but to also incorporate the factors such as risk benefit ratio, patient values and preferences, and resource consideration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It was clear that additional research is needed across the continuum of LHI patient care. Unfortunately, this type of clinical research could be difficult to execute given the complexity and variability of these patients. In the meantime, these guidelines can be used as a road map in treating patients with LHI. It should be noted that all guidelines need to be considered in the context of regional needs and resources, particularly when it comes to weak recommendations. The panel encourages guideline users to consider the nuances of the evidence presented as they implement these recommendations in their own practice. As the evidence grows, these recommendations will need to be reviewed accordingly. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Slide Presentation" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
      <FieldValue Value="Patient-centeredness" />
      <FieldValue Value="Timeliness " />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Torbey MT, BÃ¶sel J, Rhoney DH, Rincon F, Staykov D, Amar AP, Varelas PN, JÃ¼ttler E, Olson D, Huttner HB, Zweckberger K, Sheth KN, Dohmen C, Brambrink AM, Mayer SA, Zaidat OO, Hacke W, Schwab S. Evidence-based guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine. Neurocrit Care. 2015 Feb;22(1):146-64. [172 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25605626&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2015 Feb" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="German Society for Neuro-Intensive Care and Emergency Medicine - Medical Specialty Society" />
      <FieldValue Value="Neurocritical Care Society - Medical Specialty Society" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Neurocritical Care Society&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Management of Large Hemispheric Infarction Guideline Committee&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: M. T. Torbey, Cerebrovascular and Neurocritical Care Division, Department of Neurology and Neurosurgery, The Ohio State University Wexner Medical Center Comprehensive Stroke Center, Columbus, OH, USA; J. B&amp;ouml;sel, Department of Neurology, University of Heidelberg, Heidelberg, Germany; D. H. Rhoney, Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA; F. Rincon, Division of Critical Care and Neurotrauma, Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA; D. Staykov, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany; A. P. Amar, Department of Neurosurgery, University of Southern California, Los Angeles, CA, USA; P. N. Varelas, Neurocritical Care Division, Henry Ford Hospital, Detroit, MI, USA; E. J&amp;uuml;ttler, Department of Neurology, Ostalb-Klinikum Aalen, Aalen, Germany; D. Olson, University of Texas Southwestern, Dallas, TX, USA; H. B. Huttner, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany; K. Zweckberger, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany; K. N. Sheth, Division of Neurocritical Care and Emergency Neurology, Department of Neurology, and Neurosciences Intensive Care Unit, Yale School of Medicine &amp;amp; Yale New Haven Hospital, New Haven, CT, USA; C. Dohmen, Department of Neurology, University of Cologne, Cologne, Germany; A. M. Brambrink, Department of Anesthesiology and Perioperative Medicine, Neurology and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA; S. A. Mayer, Institute for Critical Care Medicine, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA; O. O. Zaidat, Neurointerventional Program, Medical College of Wisconsin, Milwaukee, WI, USA; W. Hacke, Department of Neurology, University of Heidelberg, Heidelberg, Germany; S. Schwab, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Conflict of Interest&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Michel T Torbey has received speaker honorarium from Genentech, support from the National Institutes of Health (NIH). Julian B&amp;ouml;sel has received speaker honoraria and travel support from Covidien, Sedana Medical, and Orion Pharma. Denise H. Rhoney declares that she has no conflict of interest. Fred Rincon declares that he has research and salary support from the American Heart Association (12CRP12050342). He has also received consultant fees from Bard Medical Inc. Dimitre Staykov declares that he has no conflict of interest. Arun Amar declares that he has no conflict of interest. Panayiotis Varelas has participated in Advisory Boards of Pfizer and UCB. Eric J&amp;uuml;ttler has received a speaker's honorarium from BMS/Pfizer, a consultant's honorarium from Boehringer Ingelheim, and a research grant from the German Research Foundation (Deutsche Forschungsgemeinschaft). DaiWai Olson declares that he has no conflict of interest. Hagen B. Huttner declares that he has no conflict of interest. Klaus Zweckberger declares that he has no conflict of interest. Kevin N Sheth declares that he received research support from Remedy Pharmaceuticals, Inc for GAMES-RP. Christian Dohmen declares that he has no conflict of interest. Ansgar M Brambrink is Co-PI on an investigator-initiated multicenter trial that is funded by Karl Storz America, Culver City, CA. He also receives research funds from the International Anesthesia Research Society (PI; laboratory experiments), the National Institutes of Health (Site PI; laboratory experiments). Stephan Mayer declares that he has no conflict of interest. Osama O. Zaidat declares that he is on advisory board/consultant/speaker: Stryker, Covidien, and Penumbra, co-Investigator for Therapy Ischemic Stroke Trial. Werner Hacke declares that he has no conflict of interest. Stefan Schwab declares that he has no conflict of interest.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist">
      <FieldValue Value="American Association of Neurological Surgeons - Medical Specialty Society" />
      <FieldValue Value="American Heart Association - Professional Association" />
      <FieldValue Value="American Stroke Association - Disease Specific Society" />
      <FieldValue Value="Congress of Neurological Surgeons - Professional Association" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;https://higherlogicdownload.s3.amazonaws.com/NEUROCRITICALCARE/b8b3b384-bfb9-42af-bb55-45973d5054a4/UploadedImages/Documents/Guidelines/LHI_Final_GL-Published.pdf&quot; title=&quot;Neurocritical Care Society Web site&quot;&gt;Neurocritical Care Society Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evidence-based guidelines for the management of large hemispheric infarction (LHI). Slide kit. 2015 Feb. 30 p. Available from the &lt;a href=&quot;https://www.neurocriticalcare.org/resources/guidelines&quot; title=&quot;Neurocritical Care Society Web site&quot;&gt;Neurocritical Care Society Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on January 31, 2017. The information was verified by the guideline developer on March 20, 2017.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>